Meeting
2017 ASCO Annual Meeting
A retrospective cohort study of PD-L1 expression in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SUPREME-HN).
Authors
Sara I. Pai
Massachusetts General Hospital Cancer Center, Boston, MA
Sara I. Pai , Ezra Cohen , Derrick Lin , George Fountzilas , Edward S. Kim , Holger Mehlhorn , Neus Baste , Daniel Clayburgh , Loren Lipworth , Carlo Resteghini , Nawar Shara , Takashi Fujii , Jun Zhang , Michael Stokes , David Lawrence , Asud Khaliq , Giovanni Melillo , Norah Shire
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT02543476
Citation
J Clin Oncol 35, 2017 (suppl; abstr 6040)
DOI
10.1200/JCO.2017.35.15_suppl.6040
Abstract #
6040
Poster Bd #
28
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
89Zr-durvalumab PD-L1 PET in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck.
First Author: Sarah Verhoeff
Poster
2021 ASCO Annual Meeting
Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis.
First Author: Hsiang-fong Kao
Poster
2019 ASCO Annual Meeting
Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1 %.
First Author: Thierry Landre
Poster
2015 ASCO Annual Meeting
KEYNOTE-055: A phase II trial of single agent pembrolizumab in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have failed platinum and cetuximab.
First Author: Steven Francis Powell